Abstract
RAS/BRAF wt mCRC pts could potentially benefit from antiEGFR treatment but only 50% of them respond. Data from CRCAssigner (CRCA) and Consensus Molecular Subtypes (CMS) classification identified transit-amplifying (TA)/CMS2 as more sensitive to antiEGFR. We aimed to evaluate different gene-expression–based classifiers for identification of RAS wt pts that may benefit from antiEGFR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
